Molecular radiotheranostics for neuroendocrine tumours
Open Access
- 1 October 2017
- journal article
- Published by Elsevier in Clinical Medicine
- Vol. 17 (5) , 462-468
Abstract
This article discusses the important role of nuclear medicine imaging and therapy in the management of neuroendocrine tumours (NETs). Somatostatin receptor scintigraphy has a high impact on patient management versus conventional imaging. Molecular radiotherapy is an important part of the management of patients with NETs. Selection of patients for molecular radiotherapy in NETs is based on uptake on their radionuclide imaging study. The imaging agent has the same mechanism of uptake as the therapeutic agent. Thus, the imaging study preselects patients that are likely to concentrate radiation within their tumours.Keywords
This publication has 35 references indexed in Scilit:
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine NeoplasmsSeminars in Nuclear Medicine, 2012
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Gut, 2011
- Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?European Journal of Nuclear Medicine and Molecular Imaging, 2011
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to OctreotideJournal of Clinical Oncology, 2010
- Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II studyAnnals of Oncology, 2009
- Assessment of the efficacy and toxicity of 131I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumoursBritish Journal of Cancer, 2008
- Optimization of Equipment and Methodology for Whole Body Activity Retention Measurements in Children Undergoing Targeted Radionuclide TherapyCancer Biotherapy and Radiopharmaceuticals, 2007
- Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Imaging secondary neuroendocrine tumours of the liver: comparison of I123 metaiodobenzylguanidine (MIBG) and In111-labelled octreotide (Octreoscan)QJM: An International Journal of Medicine, 1996